CONMED Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by BRONSON DAVID M, was filed 14 May 2024.
Who traded when
BuySaleSince the insiders bought
- -19.9%Entry US$74.54 · Close at T+365 US$59.70
- -16.6%Entry US$72.80 · Close at T+365 US$60.73
- -18.9%Entry US$70.34 · Close at T+365 US$57.08
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate CONMED Corp Hold (neutral), based on 6 analysts. Average price target: US$46.83.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 4,000 shares0Common StockSEC:0000816956-26-000115:0
- 1,124 shares@ US$53.66Common StockSEC:0000816956-26-000115:1
- 500 shares0Common StockSEC:0000816956-26-000105:0
- 668 shares0Common StockSEC:0000816956-26-000075:0
- 668 shares0Common StockSEC:0000816956-26-000065:0
- 668 shares0Common StockSEC:0000816956-26-000067:0
- 668 shares0Common StockSEC:0000816956-26-000069:0
- 668 shares0Common StockSEC:0000816956-26-000073:0
- 26 shares@ US$39.904.1% of flowCommon StockSEC:0000816956-26-000029:1
- 75 shares0Common StockSEC:0000816956-26-000029:0
- 152 shares0Common StockSEC:0000816956-26-000011:0
- 257 shares@ US$41.2136.0% of flowCommon StockSEC:0000816956-25-000063:0
- 118 shares@ US$40.6311.1% of flowCommon StockSEC:0000816956-25-000061:1
- 375 shares0Common StockSEC:0000816956-25-000061:0
- 3,500 shares@ US$43.004.7% of flowCommon StockSEC:0000816956-25-000059:0
- 1,114 shares@ US$45.71100.0% of flowCommon StockSEC:0000816956-25-000053:1
- 4,000 shares0Common StockSEC:0000816956-25-000053:0
- 2,164 shares@ US$44.001.1% of flowCommon StockSEC:0000816956-25-000044:1
- 7,500 shares0Common StockSEC:0000816956-25-000044:0
- 897 shares@ US$53.517.4% of flowCommon StockSEC:0000816956-25-000042:1
- 1,103 shares@ US$53.53515.0% of flowCommon StockSEC:0000816956-25-000042:0
- 598 shares@ US$52.451.0% of flowCommon StockSEC:0000816956-25-000033:0
- 479 shares0Common StockSEC:0001127602-25-016753:0
- 479 shares0Common StockSEC:0001127602-25-016771:0
- 479 shares0Common StockSEC:0001127602-25-016768:0
25 of 2730 declarations
About CONMED Corp
The largest trade in the CONMED Corp (Healthcare & Pharma) record is a sale by director Jerome J. Lande: EUR 56,184,946 on February 19, 2016. Curt R. Hartman (President, CEO and Chair) sold EUR 4,610,142 on June 3, 2021, and Pat Beyer EUR 2,102,364 on October 29, 2021. The 242 sales total EUR 136,185,904 (median EUR 234,253), against 23 purchases worth EUR 1,595,284 (median EUR 16,464), or 9% of open-market trades.
The largest purchases are by director Mark E. Tryniski, EUR 193,730 on March 6, 2017, Pat Beyer (Chief Operating Officer), EUR 192,096 on April 30, 2024, and Curt R. Hartman, EUR 189,631 on March 10, 2017. From April 30 to May 13, 2024, 4 filers bought EUR 507,035 worth. Across the full history, 11 purchase filings are classed as clustered.
Read moreShow less
Of 1,069 filings from 34 filers, 460 are option exercises and 315 are grants. Daniel Jonas (EVP Legal Affairs, Gen. Counsel) files 123, Terence M. Berge 98 and John Jed Kennedy 91. Volume has shrunk, from 174 filings in 2021 to 27 in 2025. The last twelve months hold 17, of which 2 sales. The 23 purchases tracked at 90 days show a median of 6.3% with 65% of cases positive, recorded past results, not a forecast.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
